{"id":13594,"date":"2023-11-30T20:04:34","date_gmt":"2023-11-30T14:34:34","guid":{"rendered":"https:\/\/farratanews.online\/cases-of-covid-variant-ba-2-86-have-tripled-in-a-two-week-timeframe-cdc-report\/"},"modified":"2023-11-30T20:04:34","modified_gmt":"2023-11-30T14:34:34","slug":"cases-of-covid-variant-ba-2-86-have-tripled-in-a-two-week-timeframe-cdc-report","status":"publish","type":"post","link":"https:\/\/farratanews.online\/cases-of-covid-variant-ba-2-86-have-tripled-in-a-two-week-timeframe-cdc-report\/","title":{"rendered":"Cases of COVID variant BA.2.86 have tripled in a two-week timeframe: CDC report"},"content":{"rendered":"
[ad_1]\n<\/p>\n
Cases of the COVID-19 variant<\/u> Omicron BA.2.86, also known as Pirola, have tripled in two weeks, comprising between 5% and 15% of all infections, according to the Centers for Disease Control and Prevention (CDC).<\/p>\n
The COVID-19 variant Omicron BA.2.86 \u2014 as well as its offshoots, including JN.1 \u2014 has been reclassified as a “variant of interest” by the World Health Organization<\/u> (WHO).<\/p>\n
Despite its prevalence, BA.2.86 “does not appear to be driving increases in infections or hospitalizations in the United States,” the CDC stated in its report.<\/p>\n
OVER HALF THE PEOPLE WHO GET COVID HAVE LINGERING SYMPTOMS AFTER 3 YEARS, NEW STUDY FINDS<\/u><\/strong><\/p>\n Both the CDC and WHO agree that “the public health risk<\/u> posed by this variant is low compared with other circulating variants.”<\/p>\n The updated COVID-19 vaccines<\/u> that were approved by the FDA in September are believed to “increase protection against BA.2.86, as they do for other variants,” the CDC noted.<\/p>\n